55 results about "Antiplatelets drugs" patented technology

A pharmaceutical composition comprising at least one of components (a) and at least one of components (b) shown in below: (a) a compound represented by the general formula (I) (wherein R1 represents a hydrogen atom or a hydroxyl group) or an acid addition salt or hydrate thereof; and (b) an ameliorant of cerebral circulation, a vasodilator, a cerebral protecting drug, an brain metabolic stimulants, an anticoagulant, an antiplatelet drug, a thrombolytic drug, an amelirant of psychiatric symptom, a antihypertensive drug, an antianginal drug, a diuretic, a cardiotonic, an antiarrhythmic drug, an antihyperlipidemic drug, an immunosuppressant, or a pharmaceutically acceptable salt (except the components shown in (a)). It is useful as a preventive or remedy for cerebrovascular disorders and cardiac diseases.

Disclosed is an antithrombotic neurovascular device useful for the treatment of brain aneurysms and / or acute ischemic stroke. The device comprises a mechanical structure, which may be a stent, stent-like structure, or flow diverter, and a drug-eluting coating. This device is designed for local delivery of antiplatelet medication to the site of device implantation in order to improve outcomes for the population of brain aneurysm and / or acute ischemic stroke patients currently being treated with stents, and for use with patients presenting with ruptured aneurysms, in whom systemic dual antiplatelet therapy is contraindicated. The coating comprises an antiplatelet drug, preferably, a GPIIb / IIIa receptor inhibitor, more preferably, abcixmab, and optionally comprises a polymeric binder that functions as a drug modulating polymer. Also disclosed are methods for producing the antithrombotic neurovascular device, and using the device for the treatment of brain aneurysms and / or acute ischemic stroke.

A slide fastener bioabsorbable stent is applied as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent includes a snap fastener stent, an edge slide fastener stent, a middle slide fastener stent, and a double fastener stent. The slide fastener bioabsorbable stent has good degradability and biocompatibility, and is more suitably used as a pediatric vascular stent, with which no late-onset stent thromboses after implanted, and thus it is not necessary to long-term take antiplatelet drugs and the subsequent surgical operation may not be affected. Also, it has a strong support, and thus can be widely used as a cardiovascular system stent or a lumen stent in the disease of cardiovascular or narrow lumen. The slide fastener bioabsorbable stent has simple production and convenient drug carrying, which can be used as a carrier of medicine or gene treatment. The stent can be matched with a delivery system, hence the difficulty of the surgery operation is reduced. Many animal experiments show that slide fastener bioabsorbable stent has high success ratio when being used, and has apparent curative effect and good clinical application prospect.

The present invention relates to an immunologic mechanism for gastrointestinal diseases such as non-infectious gastrointestinal diseases including child non-infectious gastrointestinal diseases, and anovel application of a phosphodiesterase inhibitor and / or an antiplatelet drug to treatment of the gastrointestinal diseases such as the non-infectious gastrointestinal diseases.

The invention belongs to the technical field of antiplatelet drugs and provides 1,4-disubstituted piperazine derivatives and pharmaceutically acceptable salts thereof. The 1,4-disubstituted piperazine derivatives have a general structural formula I. In the general structural formula I, x, y, m, R1, R2, R3 and R4 are defined in the patent specification. The invention relates to a preparation method of the 1,4-disubstituted piperazine derivatives, discloses a drug composition containing the 1,4-disubstituted piperazine derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the 1,4-disubstituted piperazine derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.

The invention relates to an application of a novel slide buckle bio-absorbable stent in manufacture of a cardiovascular system or a lumen stent for cardiovascular or luminal stenosis diseases. The application has the advantages as follows: the novel slide buckle bio-absorbable stent has good degradability and biocompatibility and is applicable to pediatric intravascular stents, and late stent thrombosis cannot occur after implantation, so that antiplatelet drugs are not required to be taken for a long time, and possible subsequent surgical operations cannot be affected; the support force is high, the novel slide buckle bio-absorbable stent can be taken as a cardiovascular system stent or a lumen stent and can be widely applied in the cardiovascular or luminal stenosis diseases; the manufacture is simple and convenient, medicine carrying is facilitated, and the stent can be used as a drug or gene therapy carrier; the stent is equipped with a delivery system at the same time, and the operation difficulty is reduced; and a large number of animal experiments show that the novel slide buckle bio-absorbable stent has a higher success rate during the usage, the curative effect is remarkable, and the stent has a better clinical application prospect.

The invention relates to a kit for detecting an antiplatelet drug in blood plasma through an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The pretreatment processis simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The present invention discloses a valve with anti-thrombosis and anti-calcification functions, and a preparation method and an application of the valve. The valve comprises a valve base and a zwitterionic copolymer covalently connected to the valve base. During preparation, the valve base is firstly soaked in a glutaraldehyde solution to obtain a cross-linked valve; and then the cross-linked valveis soaked in a zwitterionic polymer solution with a concentration of 0.1-5 wt% for reaction for 2-4 days, and then reduction with a reducing agent is conducted to obtain the valve with the anti-thrombosis and anti-calcification functions. The valve material is subjected to anti-thrombosis and anti-calcification treatments, so that after the valve is implanted in patients, risks of valve leaflet thrombosis can be reduced, valve leaflet thickening and transvalvular differential pressure increase are prevented, a long-term hydrodynamic performance is improved, patients can avoid or reduce uses of anticoagulant and antiplatelet drugs, risks of patient bleeding are reduced, besides, aldehyde residues in the valve leaflet tissues are reduced, biocompatibility and anti-calcification ability areimproved, and ultimately complications of valve leaflet thrombosis are reduced and service life of the valve is extended.

The invention provides a reagent card for detecting the therapeutic effect of thienopyridine antiplatelet drugs and an application method and application of the reagent card. The reagent card comprises four detection channels which are sequentially arranged in parallel and are independent of one another, the detection channel I contains channel I detection reagent, and the channel I detection reagent contains a lyophilized agent, wherein the lyophilized agent is obtained by firmly bonding activated dye microspheres with receptor ligand of blood platelets GpIIb / IIIa through amido bonds, then adding blood coagulation factors, and conducting freeze-drying; the detection channel II contains channel II detection reagent, and the channel II detection reagent contains a lyophilized agent serving as a blood platelet maximum activating agent; the detection channel III contains no detection reagent, the detection channel IV contains channel IV detection reagent, and the channel IV detection reagent contains a lyophilized agent serving as a blood platelet P2Y12 receptor activating agent and P2Y1 receptor antagonist. By means of the reagent card, the therapeutic effect of thienopyridine antiplatelet drugs can be detected easily, fast, conveniently and accurately.

The invention provides a method for realizing platelet patterning by polyphenols on material surface. According to the method, a polyphenol and metal ion mixed solution is prepared under chelation between the polyphenols and metal ions and is added dropwise to a seal surface with a micro-pattern, a patterned seal made of the polyphenol material is obtained and finally used for performing micro-contact printing on a target material, and the patterned polyphenol material surface is obtained. After the patterned polyphenol material surface makes contact with platelets, the platelets selectively adhere to areas not covered with the polyphenol material, so that patterning regulation of the platelets is realized. Hydrophilic polymers or bioactive proteins need not to be introduced, and the method has the characteristics of being low in cost and simple and convenient to operate. The prepared platelet patterned surface is expected to be applied to fields such as platelet adhesion detection, antiplatelet drug therapy and evaluation and the like.

The invention relates to a method for detecting an antiplatelet drug in blood plasma by using an ultra-high performance liquid chromatography-tandem mass spectrometry technology. The method has the advantages that the pretreatment process is simple, the cost is low, the sensitivity is high, the specificity is high, separation and detection of the antiplatelet drug are completed within 5 min, the accuracy degree and precision basically meet the requirements, the method can be used for quantitative analysis of the clinical antiplatelet drug, and a reliable detection method is provided for monitoring the treatment concentration of the clinical antiplatelet drug.

The invention discloses a SNP marker relevant with treatment of ischemic stroke through antiplatelet drug clopidogrel and application thereof, as well as a special amplification primer and a special extension primer for detecting the marker. The SNP marker is combination of rs6686001, rs2302429, rs2242480, rs4244285 and rs2046934. Sequences of each marker, the special amplification primer and the special extension primer are sequentially respectively as shown in SEQ ID No. 1-20. According to the SNP marker combination, clopidogrel-resistant and clopidogrel-effective ischemic stroke people can be distinguished well. The SNP marker, the amplification primer thereof and a relevant kit can be used for clinical medication guidance for adopting the antiplatelet drug clopidogrel to treat ischemic stroke patients, medicine resistance is prevented, and a treatment effect is enhanced.

The invention relates to the technical field of medical examination, and specially relates to a method for simultaneous determining concentrations of ticagrelor and active metabolites and endogenous adenosine thereof in human plasma by liquid chromatography-mass spectrometry. The concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma are simultaneously determined by adopting a liquid chromatography-mass spectrometry technology. The method comprises the following steps: A, simultaneously determining the concentrations of ticagrelor, active metabolites of ticagrelor and endogenous adenosine in human plasma; B, all the samples to be detected can be subjected to peak determination under the same chromatographic and mass spectrometric conditions;and C, simultaneously extracting to-be-detected substances with different polarities in the sample. The method has the advantages that the adenosine concentration change in the blood plasma in the body of the patient and the relationship between the adenosine concentration change and the concentration of the ticagrelor and the active metabolite thereof in the blood plasma after the antiplatelet drug ticagrelor is taken can be accurately, simply, conveniently and quickly evaluated. In addition, pretreatment and chromatographic and mass spectrometric conditions are optimized, so that the determination method is simple, quick and sensitive to operate, high in specificity and good in repeatability.

The invention belongs to the technical field of biology, and particularly to a molecular marker for diagnosis of diabetes and application thereof. For the problem that currently, no reliable biomarkercan perform risk prediction and early diagnosis on the diabetes, the following solution is proposed that the molecular marker comprises a kit and diagnostic primers, wherein the kit is internally provided with a chip, the chip comprises a gene chip, a gene primer and a molecular marker, the diagnostic primers comprise the forward primer and the reverse primer, and the forward primer and the reverse primer are both set to have RNA molecule sequences. Trough the detection of items related to a thrombus molecular marker, not only is further knowing of complications of DM vascular injuries and the pathogenesis of thrombosis facilitated, but also a basis is provided for using anticoagulant antiplatelet drugs for treatment, and the detection of molecules of type 2 diabetes patients has important clinical significance for the early prevention or intervention of thrombogenesis and vasculopathy.

The invention belongs to the technical field of drug application, relates to a new use of a tumor vascular disrupting agent DMXAA, and in particular relates to the use of the tumor vascular disrupting agent DMXAA in preparation of antiplatelet and antithrombotic drugs, wherein the tumor vascular disrupting agent DMXAA has the structure represented by the formula (I). Through in-vitro, ex-vivo and in-vivo tests of the DMXAA, results show that a DMXAA antiplatelet mechanism is different from that of known antiplatelet drugs such as aspirin, clopidogrel, prasugrel, ticagrelor, cilostazol and fibrinogen receptor antagonists, and the DMXAA simultaneously has dual activities of TXA2 generation inhibition and TXA2 receptor antagonism; and the experimental results indicate that the DMXAA can be used for the preparation of the effective and safe antiplatelet and antithrombotic drugs, and is used for prevention and treatment of arterial thrombotic diseases, such as coronary heart disease, apoplexy, peripheral vascular disease and the like.

The invention belongs to the technical field of antiplatelet drugs and provides thiomorpholine-containing pyrrole derivatives and pharmaceutically acceptable salts thereof. The thiomorpholine-containing pyrrole derivatives have a general structural formula I. In the general structural formula I, m and R are defined in the patent specification. The invention relates to a preparation method of the thiomorpholine-containing pyrrole derivatives, discloses a drug composition containing the thiomorpholine-containing pyrrole derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the thiomorpholine-containing pyrrole derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.

The invention relates to novel thienopyridine compounds or pharmaceutically acceptable salts of the novel thienopyridine compounds, medicine compositions comprising the thienopyridine compounds as active ingredients, and an application of the novel thienopyridine compounds or pharmaceutically acceptable salts of the novel thienopyridine compounds to the preparation of an antiplatelet drug. Het is trimethylpyrazinyl, pyrazinyl, pyridyl, thienyl, or indolyl; R1 is H or cyclopropylethanone; R2 is H or acetoxyl.

The invention discloses an aspirin resistance relevant GPIa gene polymorphic site and application. Antiplatelet drugs (especially aspirin) have great significance in treatment of ischemic stroke, but the current survey result shows that many patients in ischemic stroke relapse into the stroke even after taking the antiplatelet drugs, and the phenomenon is called as antiplatelet drug resistance. The applicant determines the aspirin resistance relevant GPIa gene polymorphic site GPIa(C807T), and designs a primer for detecting the polymorphism of the site for the site, the primer can be used for preparing a kit for screening out aspirin resistance patients so as to select antiplatelet drugs for patients of ischemic stroke, and the aspirin resistance and stroke relapse rate are decreased.

Embodiments of the invention provides methods and devices which enable a quick, easy, and cost-effective test for detecting the presence of coagulation factor (CF) inhibitors and platelet (P) inhibitors within small volumes of patient-derived liquid samples. The inventive approach reduces the need for elaborate and time-consuming sample testing or larger quantities of a sample to be collected. The inventive approach overcomes further limitations by providing a detection method that is suitable for measuring antiplatelet drugs, as well as methods for detecting CF inhibitors which are not dependent on competition between CF inhibitors and chromogenic substrates and enzymatic cleaving, but instead relies on non-competitive configurations involving the use of sequential binding moieties with specificity toward CF / P inhibitors and subsequent complexes and / or competitive configurations involving the use of binding moieties that will compete for CF inhibitors against either modified CF inhibitors or other competing moieties.

The invention relates to the technical field of platelets, in particular to a platelet treatment guidance method based on drug gene polymorphism and thromboelastography. The method comprises the following steps: S1, drug gene detection; S2, whole blood genome DNA sequencing; S3, metabolic classification; S4, TEG detection; and S5, result analyzing. In the invention, the risk of new stroke within 90d can be effectively reduced by guiding the anti-platelet treatment of the mild ischemic stroke according to the drug gene polymorphism in combination with TEG, and the bleeding risk is not increased. The gene detection is combined with the TEG, so that patients insensitive to antiplatelet drug therapy can be found in time, a new basis for selection of anti-platelet treatment drugs is provided, patients with ischemic stroke can select the anti-platelet drugs more accurately and reasonably, an individualized anti-platelet treatment scheme is formulated, the risk of stroke recurrence is effectively reduced, and the method has important guiding significance for secondary prevention of ischemic stroke and is worthy of clinical popularization and application.

The invention belongs to the technical field of biology, and provides a special primer for detecting SNP sites of drug-resistance related genes for anticoagulant and antiplatelet medication. The special primer comprises a primer group 1 and a primer group 2, wherein the primer group 1 is a specific PCR primer composed of 15 pairs of primers, and the primer group 2 is a single base extension primercomposed of 15 primers. The invention further provides a reparation for detecting the SNP sites of drug-resistance related genes for anticoagulant and antiplatelet medication, and a method for detecting the SNP sites of the drug-resistance related genes for anticoagulant and antiplatelet medication. By adopting the special primer provided by the invention, the detection time can be greatly shortened, the cost is saved, and the special primer has a very high application value for guiding precise medication of six clinically common anticoagulant and antiplatelet drugs, and is suitable for popularization and application.

The invention discloses an aspirin resistance-related P2Y1 gene polymorphic site and an application. Antiplatelet drugs (particularly aspirin) play a crucial role in the prevention of ischemic stroke; however, current investigation result indicates that many ischemic stroke patients even taking the antiplatelet drug still suffer relapse of stoke, and the phenomenon is called antiplatelet drug resistance. The applicant defines an aspirin resistance-related P2Y1 gene polymorphic site: P2Y1 (A745G) and designs a primer for detecting the site polymorphism; and the primer can be used for preparing a kit for screening aspirin resistant patients so as to select antiplatelet drugs for the ischemic stroke patients and reduce the aspirin resistance and stoke relapse.

The invention belongs to the technical field of antiplatelet drugs and provides thiomorpholine-containing pyrrole derivatives and pharmaceutically acceptable salts thereof. The thiomorpholine-containing pyrrole derivatives have a general structural formula I. In the general structural formula I, m and R are defined in the patent specification. The invention relates to a preparation method of the thiomorpholine-containing pyrrole derivatives, discloses a drug composition containing the thiomorpholine-containing pyrrole derivatives or their pharmaceutically acceptable salts as active ingredients, and also discloses a use of the thiomorpholine-containing pyrrole derivatives and their pharmaceutically acceptable salts in antiplatelet drugs.

The invention relates to an application of evodiamine in preparation of antiplatelet drugs. The antiplatelet effect is resisting collagen-induced platelet aggregation or resisting thrombin-induced platelet blood clot retraction. An optical turbidimetry detection result shows that the sensitivity is high, the evodiamine has a remarkable inhibition effect on collagen-induced human platelet aggregation and thrombin-induced platelet blood clot retraction, the evodiamine is not limited to inhibition of collagen-induced platelet aggregation, can be used for exploring influences of the evodiamine andother platelet activators (collagen, arachidonic acid, ADP, epinephrine, restomycin and the like) on effects and related functions of platelets, and can also be used for monitoring existing antiplatelet treatment.

The invention belongs to the technical field of biology, relates to the field of medical apparatuses and instruments and in particular to novel application of a recombinant hCREG glycoprotein and application thereof on a coronary stent. The recombinant hCREG glycoprotein disclosed by the invention is used for preparing a pharmaceutical composition capable of inhibiting inflammations and / or inhibiting atherosclerosis. The recombinant hCREG glycoprotein disclosed by the invention is capable of maintaining the advantages of the existing drug eluting stent, inhibiting development of atherosclerosis and promoting blood vessel reendothelialization, and has important clinical significances for solving the problems that restenosis is caused by new atherosclerosis of the existing coronary stent and patients need to take antithrombotic and antiplatelet drug after the operation.

The invention discloses compounds with antithrombotic effects with the structure of formula I and pharmaceutically acceptable salts thereof. According to the compound, R can be hydrogen, methyl, ethyl, propyl, isopropyl, nitro, cyano, halogen and trifluoromethyl. The invention also discloses a method for preparing the compounds, a pharmaceutical composition by taking the compounds and the pharmaceutically acceptable salts as active ingredients, and application of serving as antiplatelet drugs, particularly for preparation of medicines for preventing or treating the coronary syndrome, myocardial infarction, myocardial ischemia and other cardiovascular and cerebrovascular diseases caused by platelet aggregation.

The invention discloses an aspirin resistance-related GPIIIa gene polymorphic site and an application. An antiplatelet drug (particularly aspirin) plays a crucial role in the prevention of ischemic stroke; however, current investigation results indicate that many ischemic stroke patients taking the antiplatelet drug still suffer relapse of stroke even, and the phenomenon is called antiplatelet drug resistance. The applicant defines an aspirin resistance-related GPIIIa gene polymorphic site GPIIIa (A1166C) and designs a primer for detecting the site polymorphism for the site, wherein the primer can be used for preparing a kit for screening aspirin resistant patients so as to select an antiplatelet drug for ischemic stroke patients and reduce the aspirin resistance and stroke relapse.

The invention discloses an SNP marker related to accurate medication of an antiplatelet drug clopidogrel for treating ACS, an application of the SNP marker and a specific amplification primer for detecting the marker. The SNP marker is rs16934371 on a KCNMA1 gene, can well distinguish CAS crowds for whom the clopidogrel is low in efficacy and effective, and helps accurate medication of the clopidogrel, and the application of the SNP marker and the amplification primer thereof in preparation of related detection kits are clarified.

The present invention relates to the application of miRNA in regulating the expression level of Gelsolin and its application in antiplatelet therapy, and the miRNA is miR‑124. It also relates to a method for screening potential anti-platelet therapeutic drugs by screening agents that regulate the above-mentioned miRNA in platelets. Screening experiments showed that ligustrazine, panax notoginseng saponins and aspirin could regulate the level of miR‑124 in platelet cells, thus playing a role in antiplatelet therapy.